GlassScriptPhysician profile
Laura G Aisenberg
NPI 1093800757
$12,166.28
in general payments reported to CMS, 2019-2025
64 companies · $1,551 in 2025
The $1,551 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,283 · 2020: $1,287 · 2021: $2,098 · 2022: $1,625 · 2023: $1,972 · 2024: $2,350 · 2025: $1,551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,873.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,873.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,839.39 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $1,102.63 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $978.81 | 2019-2025 | Otezla, Repatha, Evenity |
| Lilly USA, LLC | $927.49 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $811.59 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $637.56 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $632.80 | 2019-2025 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $568.62 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $394.74 | 2019-2025 | Trintellix |
| Astellas Pharma US INC | $363.10 | 2019-2023 | Veozah |
| Glaxosmithkline, LLC. | $356.61 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Boston Scientific Corporation | $253.89 | 2019-2025 | Watchman Flx, Bodyguardian, General - Pain Management |
| Merck Sharp & Dohme LLC | $253.21 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Teva Pharmaceuticals USA, INC. | $191.85 | 2019-2025 | Ajovy, Austedo Xr |
| Biohaven Pharmaceuticals, INC. | $180.94 | 2021 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Aisenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.